Idiopathic pulmonary fibrosis (IPF) is a serious interstitial lung disease (ILD) with a poor prognosis. To date, the causes of IPF have not been clearly established. There is currently no drug that can effectively treat IPF. The anti-fibrosis drug pirfenidone and the immunosuppressive agent azathioprine are typically used for treatment of IPF patients, but the effect if not significant. Thus, it is urgent to develop effective and specific therapeutic agents.
Taking this into consideration, there have been many studies conducted on the process of transcription, namely on the mechanisms and roles of transcription factors in modifying the functions of various proteins. Many of these studies have focused mainly on the modification of lysine in acetic acid, one of the most basic units of proteins. One type of modification is the acetylation of histone proteins, which affect protein expression after the translation process is complete. Despite such studies, there is still no available medication that has been developed specifically for IPF.
This technology suppresses the activation of histone acetyltransferase p300 to effectively prevent pulmonary fibrosis. Furthermore, the chemical formula of this technology is effective particularly p300, thus not affecting enzymes that are responsible for other acetylation processes that are essential for life. As such, this technology can reduce potential side effects from occurring during treatment for pulmonary fibrosis diseases.
The global fibrosis treatment market is expected to undergo rapid growth, from a market value of USD 14.2 billion in 2016 to USD 47.4 billion in 2025. As a result, there has also been an increasing demand for medications that are safer, more effective, and more easily administered.